186 related articles for article (PubMed ID: 32111352)
1. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
[TBL] [Abstract][Full Text] [Related]
2. A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS.
Narisawa-Saito M; Inagawa Y; Yoshimatsu Y; Haga K; Tanaka K; Egawa N; Ohno S; Ichikawa H; Yugawa T; Fujita M; Kiyono T
Carcinogenesis; 2012 Apr; 33(4):910-7. PubMed ID: 22345164
[TBL] [Abstract][Full Text] [Related]
3. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
4. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
[TBL] [Abstract][Full Text] [Related]
5. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
6. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
8. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
10. Ki-ras activation and expression in transformed mouse lung cell lines.
Pan YH; Nuzum EO; Hanson LA; Beer DG
Mol Carcinog; 1990; 3(5):279-86. PubMed ID: 2244960
[TBL] [Abstract][Full Text] [Related]
11. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.
Okudela K; Hayashi H; Ito T; Yazawa T; Suzuki T; Nakane Y; Sato H; Ishi H; KeQin X; Masuda A; Takahashi T; Kitamura H
Am J Pathol; 2004 Jan; 164(1):91-100. PubMed ID: 14695323
[TBL] [Abstract][Full Text] [Related]
12. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
13. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
14. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
15. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
17. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
Elife; 2022 Sep; 11():. PubMed ID: 36069770
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
[TBL] [Abstract][Full Text] [Related]
19. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
20. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
